25
Participants
Start Date
May 31, 2008
Primary Completion Date
April 30, 2009
Study Completion Date
October 31, 2009
rAvPAL-PEG
rAvPAL-PEG will be administered as a single, SC injection at dose levels of 0.001, 0.003, 0.01, 0.03, 0.1, 0.3, and 1.0 mg/kg. The duration of treatment is a single dose of study drug with 42 days (6 weeks) of follow-up.
Mount Sinai Medical Center, New York
University of Pittsburgh, Pittsburgh
University of Wisconsin, Madison
University of Minnesota Medical Center-Fairview, Minneapolis
Children's Memorial Hospital, Chicago
Washington University Center for Applied Research Sciences, St Louis
University of Utah Hospital, Salt Lake City
Oregon Health & Science University, Portland
Lead Sponsor
BioMarin Pharmaceutical
INDUSTRY